<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Psychiatry</journal-id><journal-id journal-id-type="pmc">IJPsy</journal-id><journal-title-group><journal-title>Indian Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0019-5545</issn><issn pub-type="epub">1998-3794</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21206845</article-id><article-id pub-id-type="pmc">2952159</article-id><article-id pub-id-type="publisher-id">IJPsy-45-151</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Attitudes towards taking Medicine among those patients who either received Olanzapine or First Generation Antipsychotic Agents</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chengappa</surname><given-names>N.R.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Parepally</surname><given-names>Haranath</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Brar</surname><given-names>Jaspreet S.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gopalani</surname><given-names>Aziz</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chalasani</surname><given-names>Lokaranjit</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bear</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Levine</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>*</label><label>1</label><label>2</label>K.N.R. CHENGAPPA, MD, MRCPSYCH, FRCPC, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O&#x02032;Hara Street, Pittsburgh, PA 15213-2593; and Special Studies Center at Mayview Sate Hospital, 1601 Mayview Road, Bridgeville, PA 15217-1599,</aff><aff id="aff2"><label>1</label><label>2</label>HARANATH. PAREPALLY. MD, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O&#x02032;Hara Street, and Special Studies Center at Mayview Sate Hospital, 1601 Mayview Road, Bridgeville, PA 15217-1599,</aff><aff id="aff3"><label>1</label>JASPREET S. BRAR, MD, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O&#x02032;Hara Street, and Pittsburgh, PA 15213-2593;</aff><aff id="aff4"><label>1</label><label>2</label>AZIZ GOPALANI, MD, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O&#x02032;Hara Street, Pittsburgh, PA 15213-2593; and Special Studies Center at Mayview Sate Hospital, 1601 Mayview Road, Bridgeville, PA 15217-1599,</aff><aff id="aff5"><label>1</label><label>2</label>LOKARANJIT CHALASANI, M.D., Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O&#x02032;Hara Street, Pittsburgh, PA 15213-2593; and Special Studies Center at Mayview Sate Hospital, 1601 Mayview Road, Bridgeville, PA 15217-1599,</aff><aff id="aff6"><label>2</label>JONATHAN BEAR, M.D., PH.D, Pittsburgh, PA 15213-2593; and Special Studies Center at Mayview Sate Hospital, 1601 Mayview Road, Bridgeville, PA 15217-1599,</aff><aff id="aff7"><label>1</label><label>2</label><label>3</label>JOSEPH LEVINE. M.D., Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O&#x02032;Hara Street, Pittsburgh, PA 15213-2593; and Special Studies Center at Mayview Sate Hospital, 1601 Mayview Road, Bridgeville, PA 15217-1599, and Bersheeva Mental Health Center, Ben Gurion University in die Negev, Beersheva, Israel.</aff><author-notes><corresp id="cor1"><label>*</label>Correspondence Phone: + I 412-624-4443, Fax: + I 412-383-1515,<email xlink:href="chengappakn@msx.upmc.edu">chengappakn@msx.upmc.edu</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Sep</season><year>2003</year></pub-date><volume>45</volume><issue>3</issue><fpage>151</fpage><lpage>154</lpage><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Psychiatry</copyright-statement><copyright-year>2003</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>This project evaluated the attitudes of psychiatric patients towards receiving either olanzapine or the first-generation antipsychotic agents. Newly admitted patients to a state psychiatric hospital who were either prescribed olanzapine (n=35) or other first-generation antipsychotic agents (n=34) were compared on measure of their personal attitudes toward receiving medicines using the Drug Attitude Inventory (DAI). Subjects were evaluated prior to receiving olanzapine and 8 weeks later unless they were discharged or discontinued sooner. The olanzapine-treated group recorded significantly greater improvements on their positive attitude scores toward taking the medicine, and reduced negative attitude scores relative to the comparator group. These results remained statistically significant even after correction of baseline differences between the two groups for the positive attitudes and a statistical trend persisted for negative attitude scores too. During the subsequent 30 month follow-up, significantly fewer of the olanzapine treated subjects (5, 14.3%) were readmitted to the hospital compared with 13 (38.2%) of the comparator group. These data suggest switching patients to olanzapine may improve their attitudes towards taking medicines at least in the short-term. These preliminary data need affirmation or refutation in a controlled random-assignment longer-term clinical trial where specific measures of adherence are evaluated, and where the comparators are the other second generation antipsychotic agents.</p></abstract><kwd-group><kwd>Typical antipsychotics</kwd><kwd>atypical antipsychotics</kwd><kwd>attitude</kwd><kwd>psychiatric patients</kwd><kwd>Olanzapine</kwd></kwd-group></article-meta></front></article>